Want to see HK:2162 full AI Analyst Report?
2162 Stock Chart & Stats
HK$62.80
HK$0.80(2.86%)
At close: 4:00 PM EST
HK$62.80
HK$0.80(2.86%)
Day’s Range― - ―
52-Week RangeHK$44.66 - HK$89.75
Previous CloseN/A
Volume918.50K
Average Volume (3M)1.75M
Market Cap
HK$21.04B
Enterprise ValueHK$17.31K
Total Cash (Recent Filing)HK$3.24B
Total Debt (Recent Filing)HK$696.57M
Price to Earnings (P/E)23.0
Beta0.83
Next Earnings
Mar 30, 2027EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.78
Shares Outstanding298,735,570
10 Day Avg. Volume1,466,341
30 Day Avg. Volume1,745,417
Financial Highlights & Ratios
PEG Ratio4.62
Price to Book (P/B)4.74
Price to Sales (P/S)18.85
P/FCF Ratio-12.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$107.32Price Target Upside70.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.76
Revenue Forecast (FY)HK$1.62B
Bulls Say, Bears Say
Bulls Say
Revenue ScaleRevenue has expanded substantially over the longer period shown, indicating that the company has built a materially larger commercial and development platform. This greater scale can support broader investment in antibody programs and commercialization, although maintaining growth remains important.
Gross ProfitabilityThe high gross margin shows that the underlying products and related revenue streams generate substantial gross profit before operating costs. This provides a potentially attractive foundation for future operating leverage if the company can control development, research, and administrative spending.
Balance SheetPositive equity and moderate leverage provide a comparatively stronger financial base than the company’s earnings and cash-flow results suggest. This balance-sheet capacity can support continued investment and reduce immediate pressure from debt obligations, though ongoing losses could erode flexibility.
Bears Say
Revenue DeclineThe reversal from earlier revenue expansion indicates that commercial momentum is not yet consistent. A sustained decline would weaken the company’s ability to absorb fixed research and operating costs, reduce funding available for its pipeline, and make the path toward profitability more uncertain.
Persistent LossesVery large operating and net losses show that current revenue is not sufficient to cover the company’s cost base. Persistent unprofitability can consume equity over time, constrain internal funding for drug development, and increase dependence on financing or successful future commercialization.
Cash BurnNegative operating and free cash flow demonstrate that the business is consuming substantial cash rather than funding operations internally. Continued outflows may require reliance on financing capacity, while also limiting the resources available for pipeline investment and reducing financial flexibility.
Keymed Biosciences, Inc. News
2162 FAQ
What was Keymed Biosciences, Inc.’s price range in the past 12 months?
Keymed Biosciences, Inc. lowest stock price was HK$44.66 and its highest was HK$89.75 in the past 12 months.
What is Keymed Biosciences, Inc.’s market cap?
Keymed Biosciences, Inc.’s market cap is HK$21.04B.
When is Keymed Biosciences, Inc.’s upcoming earnings report date?
Keymed Biosciences, Inc.’s upcoming earnings report date is Mar 30, 2027 which is in 183 days.
How were Keymed Biosciences, Inc.’s earnings last quarter?
Keymed Biosciences, Inc. released its earnings results on Aug 20, 2026. The company reported HK$5.014 earnings per share for the quarter, missing the consensus estimate of HK$5.376 by -HK$0.362.
Is Keymed Biosciences, Inc. overvalued?
According to Wall Street analysts Keymed Biosciences, Inc.’s price is currently Undervalued.
Does Keymed Biosciences, Inc. pay dividends?
Keymed Biosciences, Inc. does not currently pay dividends.
What is Keymed Biosciences, Inc.’s EPS estimate?
Keymed Biosciences, Inc.’s EPS estimate is -0.65.
How many shares outstanding does Keymed Biosciences, Inc. have?
Keymed Biosciences, Inc. has 298,735,570 shares outstanding.
What happened to Keymed Biosciences, Inc.’s price movement after its last earnings report?
Keymed Biosciences, Inc. reported an EPS of HK$5.014 in its last earnings report, missing expectations of HK$5.376. Following the earnings report the stock price went up 0.909%.
Which hedge fund is a major shareholder of Keymed Biosciences, Inc.?
Currently, no hedge funds are holding shares in HK:2162
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keymed Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
29.16%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Keymed Biosciences, Inc.
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
2162 Stock 12 Month Forecast
Average Price Target
HK$107.32
▲(70.89% Upside)
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―